Risk relating to the continuation and progress of the Novo Nordisk partnership
First written in FY2024. 2 of 3 entries say "Materialised", first in 2026-03-06. Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025MaterialisedAnnual report
「The Company's former business partner, Novo Nordisk A/S, notified us on 29 September 2025 that it would terminate the exclusive technology partnership and license agreement, citing its focus on its core business areas and a review of its strategy for other areas.」
The Company received notice from Novo Nordisk on 29 September 2025 terminating the exclusive partnership and license agreement. Development, manufacturing and sales rights, along with intellectual property rights and other rights, were returned to the Company. - 2026-03-06MaterialisedGeneral Meetings of Shareholders
「As a result of this notice, the rights relating to the development, manufacture and sale of our products, as well as related intellectual property rights and other rights that had been licensed out, were returned to us, and we now hold worldwide rights to HS-001 and HS-005.」
The contract review and termination risk relating to the Novo Nordisk partnership materialized, with the agreement actually being terminated. - FY2024First statedAnnual report
「Novo Nordisk A/S may lower the priority assigned to development and sales of the partnered products, and if the Company's business progress does not proceed smoothly, the agreement may be revised or terminated on terms unfavorable to the Company.」
Revenue could be affected by Novo Nordisk's progress in overseas development and sales, its priorities, and any revision or termination of the agreement.